Clinical Study to Evaluate the Safety and Feasibility of spCART-269 Injection in the Treatment of MM

Clinical Study to Evaluate the Safety and Feasibility of Targeting CD269 Chimeric Antigen Receptor Engineered T Cell (spCART-269) Injection in the Treatment of CD269-positive Multiple Myeloma

The trial is a single arm, single-center, non-randomized phase I clinical trial which is designed to evaluate the safety and efficacy of spCART-269 in treatment of relapsed or refractory multiple myeloma patients.

Study Overview

• Status: Unknown
• Conditions: Multiple Myeloma
• Intervention / Treatment: Biological: Targeting CD269 chimeric antigen receptor engineered T cells

Detailed Description

This study plans to enroll 10 patients to assess the safety and efficacy of spCART-269. Subjects who meet the eligibility criteria will receive a single dose of spCART-269 injection. The study will include the following sequential phases: Screening, Pre-treatment (Cell product preparation; Lymphodepleting Chemotherapy), Treatment and follow-up.

• Study Type: Interventional
• Enrollment (Anticipated): 10
• Phase: Phase 1

Contacts and Locations

Study Locations

• China
  • Shanghai
    • Shanghai, Shanghai, China, 200065
      • Recruiting
      • Shanghai Tongji Hospital, Tongji University School of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 75 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

1. The patient was diagnosed as active MM according to the diagnostic criteria of the International Myeloma Working Group (IMWG)

2. The patient meets any of the following:

   1. Have received at least 3 treatment options in the past and include alkylating agents, proteasome inhibitors and immunomodulators;
   2. If the patient has received a regimen containing proteasome inhibitor and immunomodulator for at least 2 courses, and the effect is not good (such as disease progression within 60 days of treatment)
3. Voluntary participation in clinical research and signing informed consent
4. Age 18-65, regardless of gender
5. Expected survival time is greater than 12 weeks
6. If the patient has received autologous hematopoietic stem cell transplantation in the past, a 90-day interval is required
7. Normal bone marrow hematopoietic function, blood routine: hemoglobin ≥ 100 g/L; absolute neutrophil ≥ 1.5×10^9/L; platelet count ≥ 100×10^9/L
8. Liver function: serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 (ULN) times the upper limit of normal value (if abnormal liver function is mainly caused by tumor infiltration, it can be ≤ 5 times the upper limit of normal value (ULN) )), bilirubin <2.0 mg/dL
9. Renal function: BUN is 9-20 mg/dL, serum creatinine ≤ 1.5 times the upper limit of normal (ULN), endogenous creatinine clearance rate ≥50 ml/min
10. Serum virus EBV, CMV, HBV, HCV, HIV and syphilis antibodies are negative
11. Heart function: good hemodynamic stability, left ventricular ejection fraction (LVEF) ≥ 45%
12. ECOG physical status score 0-2
13. Possess apheresis or sufficient venous access for venous blood, and no other contraindications for leukocyte separation
14. T cells can be successfully expanded in vitro
15. Women of childbearing age who provide negative reports of pregnancy tests with serum or urine before reinfusion
16. Adults with fertility requirements, regardless of sex, contraception within one year after treatment

Exclusion Criteria:

1. ECOG score ≥ 3 points
2. Female patients during pregnancy or lactation
3. Pathological examination revealed malignant tumor cells with T cell origin
4. Organ failure: Heart failure grade Ⅲ and Ⅳ; liver reaches Child-Turcotte liver function grade C; renal failure and uremia; respiratory failure; consciousness disorder
5. Patients with acute or chronic GVHD after allogeneic hematopoietic transplantation, or using hormones or immunosuppressants within 30 days
6. Patients with HIV infection or active hepatitis
7. There are other uncontrolled active infections
8. Those who may be allergic to cytokines
9. Those who have used any gene therapy products
10. Those who participated in other clinical studies 4 weeks before enrollment (except those who did not receive treatment in clinical studies)
11. Patients with systemic autoimmune diseases or immunodeficiency diseases
12. Definite neuropathy or psychosis, including authors of dementia or epilepsy
13. Those with lung or intestinal tumor infiltration
14. Patients that other researchers think are not suitable for enrollment

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: spCART-269; spCART-269 administered by intravenous (IV) infusion	Biological: Targeting CD269 chimeric antigen receptor engineered T cells; Targeting CD269 chimeric antigen receptor engineered T cells, single infusion intravenously; Other Names: spCART-269

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Occurrence of study related adverse events	Incidence and severity of Treatment emergent adverse events	12 weeks

Secondary Outcome Measures

Outcome Measure	Time Frame
Progression free survival (PFS)	12 months
Overall response rate (ORR)	12 months
Duration of remission (DOR)	12 months
Overall survival (OS)	12 weeks, 6 months, 12 months

Collaborators and Investigators

• Sponsor: Shanghai Tongji Hospital, Tongji University School of Medicine

Study record dates

Study Major Dates

• Study Start (Actual): July 1, 2018
• Primary Completion (Anticipated): July 1, 2022
• Study Completion (Anticipated): December 1, 2022

Study Registration Dates

• First Submitted: August 2, 2020
• First Submitted That Met QC Criteria: August 2, 2020
• First Posted (Actual): August 5, 2020

Study Record Updates

• Last Update Posted (Actual): August 5, 2020
• Last Update Submitted That Met QC Criteria: August 2, 2020
• Last Verified: August 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Cardiovascular Diseases; Vascular Diseases; Immune System Diseases; Neoplasms by Histologic Type; Neoplasms; Lymphoproliferative Disorders; Immunoproliferative Disorders; Hematologic Diseases; Hemorrhagic Disorders; Hemostatic Disorders; Paraproteinemias; Blood Protein Disorders; Multiple Myeloma; Neoplasms, Plasma Cell
• Other Study ID Numbers: 200802

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: The data sets generated and analysed during the current study are available from the corresponding author on reasonable request.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No